Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by Jane Street Group LLC

Jane Street Group LLC raised its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 54.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,351 shares of the biotechnology company’s stock after acquiring an additional 8,550 shares during the quarter. Jane Street Group LLC’s holdings in Anika Therapeutics were worth $601,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Eastern Bank acquired a new position in Anika Therapeutics in the 3rd quarter valued at about $28,000. Quest Partners LLC grew its position in Anika Therapeutics by 115.8% in the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,705 shares in the last quarter. Atria Investments Inc acquired a new position in Anika Therapeutics in the 3rd quarter valued at about $218,000. SG Americas Securities LLC grew its position in Anika Therapeutics by 43.1% in the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 2,858 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of Anika Therapeutics during the third quarter worth about $238,000. 91.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ANIK has been the subject of a number of analyst reports. StockNews.com downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Barrington Research lowered their price objective on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Anika Therapeutics Stock Performance

Shares of Anika Therapeutics stock opened at $16.19 on Friday. Anika Therapeutics, Inc. has a one year low of $15.82 and a one year high of $29.11. The company has a market cap of $237.12 million, a PE ratio of -2.43 and a beta of 0.90. The business has a 50-day simple moving average of $17.44 and a 200-day simple moving average of $22.83.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.